INTRODUCTION {#s1}
============

The notion that perioperative regional anesthesia and analgesia may improve cancer prognosis first emerged roughly a decade ago, \[[@R1]--[@R3]\] and was met by genuine enthusiasm of the anesthesia society. However, a decade later, we are still at a shortage of meaningful evidence to either support or refute this hypothesis. The difficulty of performing a large scale randomized controlled trial (RCT) with a relatively long follow-up period has led us to first look at the available data, and we have been presented with a number of retrospective \[[@R1], [@R2], [@R4]--[@R15]\] and very few prospective \[[@R6], [@R16]\] studies done on the effect of regional anesthesia and/or analgesia on the prognosis of different types of cancer.

Among several regional techniques, epidural analgesia is the most commonly employed method for operations performed in the abdominopelvic region. While there is relative abundance of retrospective and observational studies done on the effect of epidural analgesia in prostate \[[@R1], [@R5], [@R6], [@R8], [@R17]--[@R20]\] and colorectal cancer, \[[@R12], [@R13], [@R21]--[@R24]\] there are only a few that investigate gastric cancer, \[[@R4], [@R14], [@R15], [@R25]\] despite it being the fifth most common cancer worldwide. Moreover, not only do the existing studies report inconsistent results, most are based on the data of an insufficient number of a rather heterogeneous group of patients. The primary goal of this retrospective study was to compare the effect of postoperative epidural patient-controlled analgesia (PCA) vs. intravenous (IV) PCA, on recurrence and mortality in patients that received curative surgery with homogeneous surgical treatment at a high-volume center.

RESULTS {#s2}
=======

Study population, demographic data and perioperative characteristics {#s2_1}
--------------------------------------------------------------------

Figure [1](#F1){ref-type="fig"} shows the flowchart of patient sample selection. The data of 4, 098 patients were reviewed for analysis. Among these patients, 106 cases that received preoperative chemotherapy and 171 cases that underwent non-curative surgery were excluded. Additionally, 6 cases of laparoscopic gastrectomy that were converted to laparotomy, 3 cases of unclear analgesia method, and 13 cases of patient death within 30 days after surgery were excluded from analysis.

![Flowchart of patient sample selection](oncotarget-08-104594-g001){#F1}

The remaining 3, 799 cases with 374 in the IV PCA group and 3, 425 in Epidural PCA group were compared and analyzed. The opioid used in both type of PCAs was fentanyl, and all epidural PCAs contained ropivacaine. Ropivacaine was infused at a concentration of 0.15% and mixed with fentanyl at a dose of between 2--4 μg/mL at basal rates of 4--5 mL/hr, bolus doses of 1--2 mL, and lock-out times of 15 minutes. All patients were anesthetized with balanced anesthesia which consisted of the use of a volatile anesthetic and remifentanil infusion at rates between 0.1--0.3 mcg/kg/min. Demographic characteristics of the patients are listed in Table [1](#T1){ref-type="table"}. When comparing the demographic characteristics between the two groups, there was no difference in sex, height, weight, presence of hypertension, pulmonary, and liver diseases. However, there was a significant difference in age, and the presence of DM, cardiac, renal and neurologic diseases between the two groups. Greater cancer recurrence was seen with higher cancer stage (*P* = 0.012), but no difference was observed in tumor histology or resection method between the two groups.

###### Demographic and perioperative characteristics

  ---------------------------------------------------------------------
                              IV PCA\       Epidural PCA\   *P*-value
                              (*n =* 374)   (*n =* 3,425)   
  --------------------------- ------------- --------------- -----------
  Age (years)                 59.6 ± 11.6   57.5 ± 11.7     0.001

  Male sex, n                 242 (64.7)    2,280 (66.6)    0.489

  Height (cm)                 163.4 ± 8.3   164.0 ± 8.6     0.187

  Weight (kg)                 62.8 ± 11.0   62.6 ± 10.0     0.678

  Comorbidities                                             

   HTN                        108 (28.9)    916 (26.7)      0.390

   DM                         64 (17.1)     398 (11.6)      0.003

   Pulmonary disease^\*^      8 (2.1)       58 (1.7)        0.529

   Cardiac disease^†^         35 (9.4)      102 (3.0)       \< 0.001

   Renal disease^‡^           16 (4.3)      23 (0.7)        \< 0.001

   Liver disease§             20 (5.3)      141 (4.1)       0.278

   Neurologic disease^ǁ‖^     21 (5.6)      47 (1.4)        \< 0.001

  Cancer stage                                              0.012

   I                          175 (46.8)    1,867 (54.5)    

   II                         83 (22.2)     605 (17.7)      

   III                        116 (31.0)    953 (27.8)      

  Tumor histology                                           0.052

   AWD                        38 (10.2)     416 (12.1)      

   AMD                        114 (30.5)    988 (28.8)      

   APD                        132 (35.3)    1126 (32.9)     

   Mucinous                   11 (2.9)      87 (2.5)        

   SRC                        61 (16.3)     716 (20.9)      

   Other                      18 (4.8)      92 (2.7)        

  Lymphovascular invasion     130 (34.8)    1216 (35.5)     0.820

  Resection method                                          0.241

   Subtotal                   265 (70.9)    2,527 (73.8)    

   Total                      109 (29.1)    898 (26.2)      

  Anesthetic                                                

   Desflurane                 67 (17.9)     492 (14.4)      0.077

   Enflurane                  0 (0)         70 (2.0)        0.002

   Isoflurane                 87 (23.3)     1,032 (30.1)    0.006

   Sevoflurane                220 (58.8)    1,825 (53.3)    0.043

   N2O                        14 (3.7)      439 (12.8)      \< 0.001

   Propofol 1%                295 (78.9)    2,608 (76.1)    0.249

   Thiopental sodium          76 (20.3)     763 (22.3)      0.431

  Other perioperative drugs                                 

   Aspirin                    2 (0.5)       7 (0.2)         0.220

   NSAIDs                     225 (60.2)    1229 (35.9)     \< 0.001

   Ephedrine                  99 (26.5)     1,337 (39.0)    \< 0.001

   Phenylephrine              33 (8.8)      167 (4.9)       0.002

   Norepinephrine             4 (1.1)       25 (0.7)        0.523

   Esmolol                    27 (7.2)      139 (4.1)       0.007

   Labetalol                  21 (5.6)      55 (1.6)        \< 0.001

   Nicardipine                25 (6.7)      77 (2.2)        \< 0.001

  Intraoperative fluid                                      

   Colloid                    62 (16.6)     561 (16.4)      0.941

   Packed RBC                 8 (2.1)       65 (1.9)        0.692

  Recurrence                  81 (21.7)     585 (17.1)      0.031

  Mortality                   90 (24.1)     641 (18.7)      0.015
  ---------------------------------------------------------------------

Values are mean ± SD or *n* (%) of patients, HTN = hypertension, DM = diabetes mellitus AWD = adenocarcinoma, well differentiated, AMD = adenocarcinoma, moderately differentiated, APD = adenocarcinoma, poorly differentiated, SRC = signet ring cell. Pulmonary disease^\*^ = History of pulmonary diseases, Cardiac disease^†^ = History of cardiac diseases other than hypertension, Renal disease^‡^ = History of renal diseases, Liver disease^ǁǁ^ = History of liver diseases, Neurologic disease^ǁ‖^ = History of neurologic diseases including cerebrovascular accidents.

Enflurane, isoflurane and N~2~O were anesthetics that were more often used in the Epidural PCA group, while sevoflurane was more commonly used in the IV PCA group. Among other perioperative characteristics, a significantly greater proportion of patients of the IV PCA group were found to receive NSAIDs, phenylephrine, esmolol, labetalol and nicardipine than the Epidural PCA group, while ephedrine was more commonly used in the Epidural PCA group. There was no difference in intraoperative administration of colloids or packed RBC. Patients were followed up after surgery once every 3 months during the first year, every 6 months for the following 2 years, and every year thereafter for the duration of the scheduled follow-up period. Cancer recurrence occurred in 81 (21.7%) patients of the IV PCA group and 585 (17.1%) patients of the Epidural PCA group, and the mean time to recurrence was 564.34 ± 404.0 and 545.2 ± 452.7 days in the IV PCA and Epidural PCA groups, respectively, with no significant difference (*P* = 0.717). Mortality occurred in 90 (24.1%) and 641 (18.7%) patients of the IV PCA and Epidural PCA groups, respectively. The mean follow-up time in all of the patients was 53.3 ± 21.7 months.

Association between analgesia method and cancer recurrence and mortality after surgery {#s2_2}
--------------------------------------------------------------------------------------

Kaplan--Meier curves for recurrence and mortality of patients with IV PCA vs. epidural PCA are shown in Figure [2](#F2){ref-type="fig"}.

![Kaplan--Meier curves for 5-year recurrence and mortality](oncotarget-08-104594-g002){#F2}

Neither IV nor epidural PCA was found to be associated with cancer recurrence after surgery (HR, 1.092; 95% CI, 0.859 to 1.388; *P* = 0.471) (Table [2](#T2){ref-type="table"}). Factors that were related to lower recurrence were younger age and lower cancer stage. Total gastrectomy was found to be associated with greater risk of recurrence compared to subtotal gastrectomy (HR, 1.333; 95% CI, 1.132 to 1.569; *P* = 0.001). None of the anesthetics or other perioperative drugs were found to be associated with cancer recurrence. Type of postoperative PCA was also not found to be associated with mortality after open gastrectomy (*P* = 0.138) (Table [3](#T3){ref-type="table"}). Other variables associated with greater mortality included older age, higher cancer stage, total gastrectomy and the administration of intraoperative phenylephrine, norepinephrine and labetalol.

###### Univariate and multiple regression analysis of variables associated with recurrence after open gastrectomy for gastric cancer

                              Univariate Analysis    Multiple Analysis                          
  --------------------------- ---------------------- ------------------- ---------------------- ----------
  PCA type                                                                                      
   Intravenous                1                                          1                      
   Epidural                   1.032 (0.818--1.303)   0.789               1.092 (0.859--1.388)   0.471
  Age                         1.009 (1.002--1.015)   0.007               1.012 (1.005--1.020)   0.001
  Sex                                                                                           
   Male                       1                                          1                      
   Female                     0.961 (0.815--1.133)   0.637               1.014 (0.834--1.232)   0.893
  Height                      0.997 (0.987--1.007)   0.545               0.981 (0.954--1.010)   0.202
  Weight                      1.002 (0.994--1.009)   0.671               1.005 (0.996--1.014)   0.288
  Comorbidities                                                                                 
   HTN                        1.116 (0.935--1.333)   0.225               0.974 (0.800--1.185)   0.790
   DM                         1.114 (0.898--1.383)   0.325               0.975 (0.772--1.231)   0.829
  Cancer stage                                                                                  
   I                          1                                          1                      
   II                         1.364 (0.965--1.927)   0.078               1.330 (0.936--1.890)   0.112
   III                        1.867 (1.378--2.528)   \< 0.0001           1.733 (1.266--2.372)   \< 0.001
  Tumor histology                                                                               
   AWD                        1                                                                 
   AMD                        0.876 (0.693--1.106)   0.266                                      
   APD                        0.910 (0.724--1.143)   0.417                                      
   Mucinous                   1.081 (0.688--1.699)   0.735                                      
   SRC                        0.884 (0.690--1.133)   0.330                                      
   Other                      0.861 (0.544--1.365)   0.525                                      
  Lymphovascular invasion     0.973 (0.840--1.126)   0.714                                      
  Resection method                                                                              
   Subtotal                   1                                          1                      
   Total                      1.302 (1.115--1.520)   0.001               1.308 (1.112--1.538)   0.001
  Anesthetic                                                                                    
   Desflurane                 1.140 (0.919--1.415)   0.233                                      
   Enflurane                  0.474 (0.273--0.824)   0.008               0.603 (0.340--1.072)   0.085
   Isoflurane                 1.050 (0.887--1.243)   0.569                                      
   Sevoflurane                0.980 (0.841--1.142)   0.794                                      
   N2O                        0.747 (0.590--0.945)   0.015               0.823 (0.643--1.052)   0.120
   Propofol 1%                1.115 (0.934--1.331)   0.228                                      
   Thiopental sodium          0.894 (0.746--1.072)   0.226                                      
  Other perioperative drugs                                                                     
   Aspirin                    1.031 (0.257--4.129)   0.966                                      
   NSAIDs                     0.905 (0.783--1.045)   0.174                                      
   Ephedrine                  1.106 (0.946--1.292)   0.208                                      
   Phenylephrine              1.442 (1.045--1.989)   0.026               1.255 (0.893--1.763)   0.192
   Norepinephrine             2.953 (1.219--7.153)   0.016               1.866 (0.685--5.082)   0.222
   Esmolol                    1.380 (0.990--1.924)   0.058                                      
   Labetalol                  1.222 (0.673--2.221)   0.501                                      
   Nicardipine                1.570 (0.940--2.624)   0.085               1.454 (0.859--2.460)   0.163
  Intraoperative fluid                                                                          
   Colloid                    1.076 (0.892--1.297)   0.444                                      
   Packed RBC                 1.097 (0.735--1.637)   0.650                                      

CI = Confidence Interval PCA = patient controlled analgesia, HTN = hypertension, DM = diabetes mellitus, RBC = red blood cells.

###### Univariate and multiple regression analysis of variables associated with mortality after open gastrectomy for gastric cancer

                              Univariate Analysis    Multiple Analysis                           
  --------------------------- ---------------------- ------------------- ----------------------- ----------
  PCA type                                                                                       
   Intravenous                1                                          1                       
   Epidural                   0.818 (0.655--1.021)   0.075               0.695 (0.429--1.125)    0.138
  Age                         1.007 (1.001--1.013)   0.030               1.015 (1.003--1.027)    0.016
  Sex                                                                                            
   Male                       1                                          1                       
   Female                     1.110 (0.945--1.304)   0.205               0.905 (0.590--1.389)    0.649
  Height                      0.990 (0.981--0.999)   0.028               0.989 (0.964--1.014)    0.385
  Weight                      0.994 (0.986--1.001)   0.086               0.997 (0.982--1.012)    0.689
  Comorbidities                                                                                  
   HTN                        1.029 (0.878--1.207)   0.720               0.753 (0.555--1.021)    0.068
   DM                         1.130 (0.933--1.369)   0.210               1.148 (0.801--1.645)    0.452
  Cancer stage                                                                                   
   I                          1                                          1                       
   II                         1.338 (1.016--1.762)   0.038               1.745 (1.146--2.657)    0.009
   III                        1.717 (1.367--2.156)   \< 0.0001           2.193 (1.476--3.257)    \< 0.001
  Tumor histology                                                                                
   AWD                        1                                                                  
   AMD                        0.949 (0.663--1.358)   0.774                                       
   APD                        1.220 (0.860--1.731)   0.265                                       
   Mucinous                   0.963 (0.591--1.568)   0.879                                       
   SRC                        1.157 (0.795--1.684)   0.447                                       
   Other                      1.103 (0.651--1.867)   0.715                                       
  Lymphovascular invasion     1.198 (1.024--1.401)   0.025               0.865 (0.657--1.139)    0.302
  Resection method                                                                               
   Subtotal                   1                                          1                       
   Total                      1.350 (1.165--1.565)   \< 0.0001           1.473 (1.155--1.877)    0.002
  Anesthetic                                                                                     
   Desflurane                 1.149 (0.928--1.425)   0.203                                       
   Enflurane                  0.418 (0.235--0.745)   0.003               0.549 (0.297--1.012)    0.055
   Isoflurane                 0.921 (0.782--1.083)   0.318                                       
   Sevoflurane                1.118 (0.964--1.296)   0.140                                       
   N2O                        0.761 (0.610--0.950)   0.016               1.087 (0.824--1.433)    0.556
   Propofol 1%                1.017 (0.864--1.198)   0.837                                       
   Thiopental sodium          1.059 (0.895--1.252)   0.505                                       
  Other perioperative drugs                                                                      
   Aspirin                    1.535 (0.493--4.775)   0.459                                       
   NSAIDs                     0.846 (0.729--0.981)   0.027               1.074 (0.838--1.376)    0.573
   Ephedrine                  1.151 (0.993--1.334)   0.063               1.076 (0.836--1.385)    0.569
   Phenylephrine              1.455 (1.122--1.887)   0.005               2.070 (1.169--3.664)    0.013
   Norepinephrine             1.740 (0.982--3.081)   0.058               2.638 (1.040--6.690)    0.041
   Esmolol                    1.252 (0.922--1.701)   0.150                                       
   Labetalol                  1.904 (1.099--3.299)   0.022               10.623 (1.31--86.135)   0.027
   Nicardipine                1.366 (0.865--2.156)   0.181                                       
  Intraoperative fluid                                                                           
   Colloid                    0.859 (0.724--1.020)   0.083               0.758 (0.575--0.999)    0.050
   Packed RBC                 1.300 (0.929--1.818)   0.126                                       

CI = Confidence Interval PCA = patient controlled analgesia, HTN = hypertension, DM = diabetes mellitus, RBC = red blood cells.

In our PSM analysis, there was no difference in recurrence and mortality between the two groups (*P* = 0.623 and *P* = 0.695, respectively) (Table [4](#T4){ref-type="table"}).

###### Association between PCA type and post-surgery prognosis in 1-to-1 propensity score-matched gastric cancer patients that underwent open gastrectomy

  -----------------------------------------------------------------------------
  Outcome      IV PCA\       Epidural PCA\   Hazard Ratio\          *P*-value
               (*n =* 373)   (*n =* 373)     (95% CI)               
  ------------ ------------- --------------- ---------------------- -----------
  Recurrence                                 1.098 (0.756--1.596)   0.623

   No          292 (78.3)    304 (81.5)                             

   Yes         81 (21.7)     69 (18.5)                              

  Mortality                                  0.855 (0.391--1.869)   0.695

   No          283 (75.9)    291 (78.0)                             

   Yes         90 (24.1)     82 (22.0)                              
  -----------------------------------------------------------------------------

Values are *n* (%) of patients CI = Confidence Interval, PCA = patient controlled analgesia.

DISCUSSION {#s3}
==========

The perioperative period during which the patient is in the hands of the anesthesiologist is considered as a narrow window of opportunity where outcome after surgery may be affected by the choice of drugs and method of anesthesia and/or analgesia. \[[@R26]\] While surgical resection of the primary tumor can be ultimately curative, it also exposes the patient to an immunologically vulnerable period during which the patient is relatively more prone to undetectable residual disease or micrometastasis. \[[@R27]\] Although it is still largely under debate, neuraxial techniques have been suggested to be able to improve prognosis after cancer surgery. However, the findings of the present retrospective analysis show otherwise, where we failed to find any difference in recurrence or mortality after curative surgery for gastric cancer between patients that received either IV or epidural PCA for postoperative analgesia.

Proposed mechanisms through which regional anesthesia and analgesia may influence cancer outcome can be summarized into "immunomodulation" and "anti-inflammation". The immunomodulatory and anti-inflammatory effects of regional anesthesia and analgesia can be thought of as the combined output of several different mechanisms which include the attenuation of sympathetic nervous system stimulation in response to surgical stress and postoperative pain, the sparing of the need of opioids and therefore the immunosuppressant effects of such drugs, and the direct cytotoxic and anti-inflammatory effects of amide local anesthetics such as ropivacaine which was used in all of the patients included in our analysis. \[[@R27], [@R28]\].

However, whether the aforementioned immunomodulatory and anti-inflammatory effects of neuraxial techniques actually translate into a positive effect on cancer outcome is not clear, and the existing evidence present conflicting results in various types of cancer. \[[@R27]\] This is also true for gastric cancer, where epidural anesthesia and/or analgesia are commonly used. A rare randomized trial that studied the effect of epidural analgesia on cancer prognosis after major abdominal surgery concluded that cancer recurrence and mortality rates were not different between patients that received general anesthesia combined with epidural anesthesia and analgesia, compared to those that received general anesthesia with opioid analgesia. \[[@R16]\] However, the proportion of patients with gastric cancer was lower than 15% overall, and approximately 50% of patients were those with colorectal cancer. It is difficult to generalize its results mainly due to the fact that tumor biology varies significantly between organs. Also, while this study is significant in that it is probably the only randomized trial to date that studied the effect of epidural block with follow-up results up to 5 years, the analysis itself was a retrospective review of follow-up data from a previous RCT.

Although gastric cancer is the fifth most common malignancy and the third leading cause of cancer death worldwide, due to its relative uncommonness in Northern America and Europe, studies conducted in gastric cancer patients are lacking in comparison to studies in colorectal, breast, prostate and ovarian cancer. As of today, the majority of existing retrospective studies report no association between epidural anesthesia and/or analgesia and gastric cancer prognosis. Hiller et al. \[[@R4]\] reported an association between postoperative epidural analgesia and benefit on cancer recurrence and survival following surgery for esophageal, but not gastric cancer in 2014. A similar study by Cummings et al. \[[@R25]\] also published in the same year reported no association between postoperative epidural analgesia and reduced recurrence or improved survival after resection in gastric cancer patients. These results somewhat dampened the earlier enthusiasm towards the possible ability of perioperative epidural techniques to modulate cancer recurrence. A more recent retrospective study that compared combined epidural and general anesthesia with general anesthesia alone, reported no difference in long-term survival in gastric cancer patients \[[@R14]\]. Interestingly, in contrast to the aforementioned negative reports, a recent retrospective study of 4,218 patients by Wang et al. \[[@R15]\] concluded that epidural anesthesia combined with general anesthesia and postoperative epidural PCA may be associated with improved survival after resection for gastric cancer. However, despite having the merit of a largest sample size to date, this study only looked at overall survival, but not cancer recurrence after surgery. Also, the majority of patients included in this study were of advanced stage (Stage I = 28.9%, Stage II = 4.3%, Stage III = 66.9%), which may have affected their results. The patients of the present study showed a relatively more even distribution among cancer stages (Stage I = 53.8%, Stage II = 18.1%, Stage III = 28.1%) compared to the previous retrospective analysis.

Our study is not the first retrospective analysis to report negative association between epidural analgesia and gastric cancer prognosis. However, the present study seems to have great merit in that it is the first to include a very homogeneous group of patients from a reliable database of a high-volume center. Overlooking the importance of the nature of the surgical procedure as well as surgical technique can easily lead to incorrect interpretations in cancer patients. By including a homogeneous group of patients that underwent curative surgery, the present study was able to analyze the effect of epidural analgesia on recurrence after complete resection. Moreover, standardized extended (D2) lymphadenectomy was employed as a uniform surgical technique in all patients that were included in our analysis. Compared to limited (D1) lymphadenectomy, the D2 procedure has been proven to be associated with lower recurrence and gastric-cancer-related mortality, and is currently recommended as the surgical approach of choice for patients with curable gastric cancer. \[[@R29]\] The good quality database and further PSM analysis that was used in the present study has been able to increase the reliability of our results. Whether epidural analgesia is able to affect length of survival or mortality in patients undergoing palliative or non-curative surgery requires future studies.

Despite the negative results of our study, it is difficult to conclude that regional techniques are not related to outcome after gastrectomy. One may suspect that isolated use of postoperative epidural analgesia without combining intraoperative epidural anesthesia is insufficient to induce effective immunomodulatory or anti-inflammatory effects. It seems most important to acknowledge that epidural analgesia is among the many different factors associated with perioperative anesthesia care that have been suggested to have effect on tumor progression and cancer prognosis. \[[@R27]\] It would be a futile attempt to improve cancer prognosis with a single drug or procedure, and therefore clinicians should be able to achieve good analgesia, and ameliorate perioperative stress and inflammation overall. \[[@R30]\]

The association between the use of norepinephrine and phenylephrine and greater hazard for mortality is most likely due to greater hemodynamic instability and hence the need for more vasopressors in patients with poorer general condition. Due to the retrospective design of the present analysis, we cannot conclude whether such drugs are definite causes of mortality or whether they are simply markers of worse clinical outcome. Among other perioperative drugs of interest, both aspirin \[[@R31], [@R32]\] and NSAIDs \[[@R33]\] showed no association with reduced recurrence or mortality. Interestingly, the use of labetalol, a non-selective β adrenergic antagonist, was found to be associated with greater mortality after gastrectomy which is in contrary to previous reports. \[[@R34]--[@R36]\] However, the confidence interval was very wide, which indicates that our sample size was too small to draw conclusions in this aspect.

The major limitation of the present study is its retrospective nature, and thus its susceptibility to chance, bias and other confounding factors. However, we were able to include a relatively large number of patients from a single center, high-quality database in our analysis, and also performed propensity score matching with the available covariates to overcome potential selection bias somewhat. Although definitive data can only be provided by future RCTs, the results after propensity score matching in the present study should be able to add valuable insight to this debatable issue. Another limitation is that it is unclear how long the epidural catheters and PCA devices were maintained, and whether postoperative epidural analgesia was prematurely discontinued in patients included in the present analysis. Of note, it has been routine practice to start epidural PCA machines at the end of surgery and maintain infusion for 3 days in patients undergoing gastrectomies at our hospital. Also, intraoperative epidural infusions are rarely used. Therefore the results of the present study should be interpreted as a comparison between postoperative analgesic methods, and not as anesthesia. However, intermittent or complete discontinuation of epidural infusions due to hypotension or side effects of opioids are not uncommon in postoperative patients, and the absence of this data may have affected the results of our analysis.

In conclusion, postoperative epidural PCA does not seem to be associated with reduced recurrence or lower mortality in patients undergoing open curative gastrectomy for gastric cancer. Epidural analgesia should be employed as part of a comprehensive perioperative management plan, but should not be relied on as a beneficial factor for the prognosis after curative surgery in gastric cancer patients.

MATERIALS AND METHODS {#s4}
=====================

Study population and design {#s4_1}
---------------------------

This study is a retrospective analysis of patients that underwent open gastrectomy for gastric cancer with either IV or epidural PCA for postoperative pain control. The study protocol was approved by the Institutional Review Board and Hospital Research Ethics Committee of Severance Hospital, Yonsei University Health System (IRB \#4-2017--0392). The data collected for this study was from the electrical medical records of patients that underwent surgery between November 2005 and December 2010 at a single institution. Patients that received pre-operative chemotherapy or those that underwent non-curative surgery, cases that started as laparoscopic procedures but converted to laparotomy, electronic charts with unclear method of postoperative analgesia, and mortality cases that occurred within 30 days after surgery were excluded from analysis.

Retrieved demographic data of the patients included age, sex, height, weight, and comorbidities such as hypertension (HTN), diabetes mellitus (DM), pulmonary diseases, etc. In addition to type of PCA, cancer stage, extent of gastrectomy, type of anesthetic, common intraoperative drugs, and intraoperative colloid administration and red blood cell (RBC) transfusion were also analyzed as variables possibly associated with the prognosis of gastric cancer after open gastrectomy.

Statistical analysis {#s4_2}
--------------------

The primary outcome of this study was to compare the recurrence rate of gastric cancer between the two postoperative analgesia methods. Demographic and perioperative characteristics were analyzed using the Student's *t-*test for continuous variables and the chi-square test for categorical variables. Potential factors affecting cancer recurrence and mortality after gastrectomy were analyzed by the Cox proportional hazards model, and the risk of each variable was calculated as hazard ratio (HR) and 95% confidence intervals (CIs). After screening for potentially significant variables with univariate analysis, multiple Cox regression analysis was done by including factors with *P* values \< 0.2. Overall survival rates during the study period, and difference between survival curves according to PCA route were examined with the Kaplan--Meier log-rank survival analysis method. Propensity score matching (PSM) was done to reduce selection bias, and confounders used for PSM included age, sex, body mass index, presence of DM and HTN. After 1:1 matching with propensity scores calculated with logistic regression analysis with aforementioned confounding factors, the risk of recurrence and mortality with each type of PCA was analyzed with conditional Cox proportional hazard regression. *P* values less than 0.05 were considered as statistically significant. All analyses were done with SAS version 9.4.
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